Department of Clinical and Molecular Sciences, Rheumatology Unit, Polytechnic University of Marche, Ancona, Italy.
Academic Rheumatology, University of Nottingham, Nottingham, UK.
Rheumatology (Oxford). 2023 Mar 1;62(3):1108-1116. doi: 10.1093/rheumatology/keac367.
To evaluate whether US findings indicating MSU deposits and US-detected inflammation (i.e. power Doppler signal) predict gout flares over 12 months.
Gout patients on urate-lowering therapy for at least the preceding 6 months were enrolled consecutively in this 12-month prospective, observational, single-centre study. A nested case-control analysis was performed. Cases were participants with at least one flare in the follow-up period, while controls did not self-report any gout flare. The US assessment included elbows, wrists, second MCP joints, knees, ankles, and first MTP joints. The US findings indicating MSU deposits [i.e. aggregates, double contour (DC) sign and tophi] were identified as present/absent according to the Outcome Measure in Rheumatology definitions. Power Doppler signal was scored semiquantitatively. Summated scores were calculated for each US finding.
Eighty-one gout participants were enrolled, and 71 completed the study. Thirty (42.3%) of 71 participants experienced at least one flare over 12 months, with a median of 2.0 flares. Cases had a greater US burden of MSU deposits (6.7 ± 4.7 vs 2.9 ± 2.6, P = 0.01) and power Doppler signal (3.73 ± 3.53 vs 0.82 ± 1.44, P < 0.01) than controls, at baseline. The baseline US scores indicating MSU deposits and US-detected inflammation were significantly associated with the occurrence (total MSU score, adjusted odds ratio:1.75, 95% CI: 1.26, 2.43; power Doppler score, adjusted odds ratio: 1.63, 95% CI: 1.12, 2.40) and the number (total MSU score, adjusted incidence risk ratio: 1.17, 95% CI: 1.08, 1.26; power Doppler score, adjusted incidence risk ratio: 1.29, 95% CI: 1.19, 1.40) of flares over 12 months in multivariate analyses.
Baseline US findings indicating MSU deposits and US-detected inflammation are independent predictors of gout flares over 12 months.
评估 US 检查显示的 MSU 沉积和 US 检测到的炎症(即能量多普勒信号)是否可预测 12 个月内痛风发作。
连续纳入至少在之前 6 个月接受降尿酸治疗的痛风患者,进行为期 12 个月的前瞻性、观察性、单中心研究。采用巢式病例对照分析。病例组为随访期内至少有一次发作的参与者,而对照组未报告任何痛风发作。US 评估包括肘部、腕部、第二掌指关节、膝关节、踝关节和第一跖趾关节。根据风湿病学结果衡量标准,US 发现的 MSU 沉积(即聚集物、双轮廓(DC)征和痛风石)被确定为存在/不存在。能量多普勒信号进行半定量评分。计算每个 US 发现的总和评分。
共纳入 81 例痛风患者,其中 71 例完成了研究。71 例患者中有 30 例(42.3%)在 12 个月内至少发生了一次发作,中位数为 2.0 次。病例组的 MSU 沉积(6.7±4.7 比 2.9±2.6,P=0.01)和能量多普勒信号(3.73±3.53 比 0.82±1.44,P<0.01)的 US 负荷均高于对照组,基线时。MSU 沉积和 US 检测到的炎症的基线 US 评分与发作的发生(总 MSU 评分,调整后的优势比:1.75,95%可信区间:1.26,2.43;能量多普勒评分,调整后的优势比:1.63,95%可信区间:1.12,2.40)和数量(总 MSU 评分,调整后的发病风险比:1.17,95%可信区间:1.08,1.26;能量多普勒评分,调整后的发病风险比:1.29,95%可信区间:1.19,1.40)在多变量分析中均有显著相关性。
基线 MSU 沉积和 US 检测到的炎症的 US 发现是痛风发作 12 个月的独立预测因素。